<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Itraconazole</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01167</strong>&#160; (APRD00040)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis.  It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis &amp; aspergillosis. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01167/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01167/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01167.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01167.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01167.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01167.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01167.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01167">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Itraconazol</td><td>Spanish</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Itraconazolum</td><td>Latin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Itrizole</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Onmel</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Oriconazole</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sporal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sporanox</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antifungal-agents">Antifungal Agents</a></li>
<li><a href="/mesh/antiprotozoal-agents">Antiprotozoal Agents</a></li>
<li><a href="/mesh/14-alpha-demethylase-inhibitors">14-alpha Demethylase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>84625-61-6</td></tr><tr><th>Weight</th><td>Average: 705.633<br>Monoisotopic: 704.239307158</td></tr><tr><th>Chemical Formula</th><td>C<sub>35</sub>H<sub>38</sub>Cl<sub>2</sub>N<sub>8</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>VHVPQPYKVGDNFY-ZPGVKDDISA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Piperazines</td></tr><tr><th>Subclass</th><td>Phenylpiperazines</td></tr><tr><th>Direct parent</th><td>Phenylpiperazines</td></tr><tr><th>Alternative parents</th><td>Phenyltriazoles; Dichlorobenzenes; Phenol Ethers; Alkyl Aryl Ethers; Aryl Chlorides; Diazinanes; 1,3-Dioxolanes; Tertiary Amines; Polyamines; Dialkyl Ethers; Acetals; Organochlorides</td></tr><tr><th>Substituents</th><td>1,3-dichlorobenzene; phenol ether; alkyl aryl ether; chlorobenzene; aryl chloride; aryl halide; benzene; 1,4-diazinane; azole; meta-dioxolane; 1,2,4-triazole; tertiary amine; acetal; dialkyl ether; polyamine; ether; amine; organohalogen; organonitrogen compound; organochloride</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.</td></tr><tr><th>Pharmacodynamics</th><td>Itraconazole is an imidazole/triazole type antifungal agent. Itraconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 &#945;-demethylation via the inhibition of the enzyme cytochrome P450 14&#945;-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 &#945;-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Itraconazole exhibits <i>in vitro</i> activity against <i>Cryptococcus neoformans</i> and <i>Candida spp.</i> Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to <i>Cryptococcus neoformans</i> and for systemic infections due to <i>Candida albicans</i>.</td></tr><tr><th>Mechanism of action</th><td>Itraconazole interacts with 14-&#945; demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.</td></tr><tr><th>Absorption</th><td>The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>796 &#177; 185 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>99.8%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Itraconazole is extensively metabolized by the liver into a large number of metabolites, including hydroxyitraconazole, the major metabolite. The main metabolic pathways are oxidative scission of the dioxolane ring, aliphatic oxidation at the 1-methylpropyl substituent, N-dealkylation of this 1-methylpropyl substituent, oxidative degradation of the piperazine ring and triazolone scission.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Itraconazole</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00374">hydroxyitraconazole</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/376">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Itraconazole is metabolized predominately by the cytochrome P450 3A4 isoenzyme system (CYP3A4) in the liver, resulting in the formation of several metabolites, including hydroxyitraconazole, the major metabolite. Fecal excretion of the parent drug varies between 3-18% of the dose. Renal excretion of the parent drug is less than 0.03% of the dose. About 40% of the dose is excreted as inactive metabolites in the urine. No single excreted metabolite represents more than 5% of a dose.</td></tr><tr><th>Half life</th><td>21 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>381 +/- 95 mL/minute [IV administration]</li>
</ul></td></tr><tr><th>Toxicity</th><td>No significant lethality was observed when itraconazole was administered orally to mice and rats at dosage levels of 320 mg/kg or to dogs at 200 mg/kg.</td></tr><tr><th>Affected organisms</th><td><ul><li>Fungi, yeast and protozoans</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9973</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.6151</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5511</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6397</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7973</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.88</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7497</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8116</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7408</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7666</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.618</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8622</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5703</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.5279</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8219</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.5303
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7478
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.3118 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.5782
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6096
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sandoz inc</li>
<li>Ortho mcneil janssen pharmaceuticals inc</li>
<li>Stiefel laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://www.centocororthobiotech.com">Centocor Ortho Biotech Inc.</a></li>
<li>Eon Labs</li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.janssen-ortho.com">Janssen-Ortho Inc.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li><a href="http://www.patriotpharmaceuticals.com">Patriot Pharmaceuticals</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Resource Optimization and Innovation LLC</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Liquid</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Itraconazole 28 100 mg capsule Disp Pack</td><td>270.89USD</td><td>disp</td></tr><tr><td>Itraconazole powder</td><td>32.13USD</td><td>g</td></tr><tr><td>Sporanox 100 mg capsule</td><td>12.14USD</td><td>capsule</td></tr><tr><td>Itraconazole 100 mg capsule</td><td>9.46USD</td><td>capsule</td></tr><tr><td>Sporanox 10 mg/ml Solution</td><td>1.41USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6407079</td><td>1999-06-18</td><td>2019-06-18</td></tr><tr><td>United States</td><td>5633015</td><td>1994-05-27</td><td>2014-05-27</td></tr><tr><td>Canada</td><td>2142848</td><td>1999-11-16</td><td>2013-08-27</td></tr><tr><td>Canada</td><td>1336498</td><td>1995-08-01</td><td>2012-08-01</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>166.2 &#176;C</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>Insoluble</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>5.66</td><td>HTTP://WWW.RXLIST.COM</td></tr><tr><td>pKa</td><td>3.70</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>9.64e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>5.48</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>7.31</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.9</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>3.92</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>9</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>100.79</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>11</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>200.4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>74.7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Jong-Soo Woo, Hong-Gi Yi, &#8220;Antifungal oral composition containing itraconazole and process for preparing same.&#8221; U.S. Patent US6039981, issued May, 1998.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=6039981&amp;tbm=pts" target="_blank">US6039981 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00350" target="_blank">D00350 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=55283" target="_blank">55283 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505954" target="_blank">46505954 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.49927.html" target="_blank">49927 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=6076" target="_blank">6076 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL22587" target="_blank">CHEMBL22587 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000631" target="_blank">DAP000631 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA450132" target="_blank">PA450132 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2231347" target="_blank">2231347 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/itraconazole.htm" target="_blank">http://www.rxlist.com/cgi/generic/itraconazole.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/itraconazole.html" target="_blank">http://www.drugs.com/cdi/itraconazole.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/spo1411.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/spo1411.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Itraconazole" target="_blank">Itraconazole <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>J02AC02<ul class="atc-drug-tree"><li><a href="/atc/J#J">J &#8212; ANTIINFECTIVES FOR SYSTEMIC USE</a></li><li><a href="/atc/J02#J02">J02 &#8212; ANTIMYCOTICS FOR SYSTEMIC USE</a></li><li><a href="/atc/J02A#J02A">J02A &#8212; ANTIMYCOTICS FOR SYSTEMIC USE</a></li><li><a href="/atc/J02AC#J02AC">J02AC &#8212; Triazole derivatives</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>08:14.08</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=1TQN" target="_blank">1TQN <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01167.pdf?1265922809">show</a>(1.58 MB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB01167.pdf?1265922747">show</a>(73.6 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Itraconazole may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00802">Alfentanil</a></td><td>Itraconazole may increase the effect and toxicity of alfentanil.</td></tr><tr><td><a href="/drugs/DB00346">Alfuzosin</a></td><td>The antifungal increases the effect of alfuzosin</td></tr><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan</td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Itraconazole may increase the effect of the benzodiazepine, alprazolam.</td></tr><tr><td><a href="/drugs/DB01370">Aluminium</a></td><td>Aluminum-containing antacids may decrease the effect of itraconazole.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Itraconazole may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB06605">Apixaban</a></td><td>Avoid combination. Otherwise, itraconazole will likely increase apixaban serum concentration.</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>This CYP3A4 inhibitor, itraconazole, may increase the effect and toxicity of aprepitant.</td></tr><tr><td><a href="/drugs/DB01238">Aripiprazole</a></td><td>Itraconazole may increase the effect of aripiprazole.</td></tr><tr><td><a href="/drugs/DB00637">Astemizole</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Itraconazole may increase the effect and toxicity of bosentan.</td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Itraconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01222">Budesonide</a></td><td>Itraconazole may increase levels/effect of budesonide.</td></tr><tr><td><a href="/drugs/DB01008">Busulfan</a></td><td>Itraconazole reduced busulfan clearance by up to 25% in patients receiving itraconazole compared to those that did not receive it. Concomitant therapy may lead to toxic plasma levels of busulfan. </td></tr><tr><td><a href="/drugs/DB06772">Cabazitaxel</a></td><td>Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01373">Calcium</a></td><td>Calcium-containing antacids may decrease the effect of itraconazole.</td></tr><tr><td><a href="/drugs/DB06724">Calcium carbonate</a></td><td>The antacid, calcium carbonate, may decrease the effect of itraconazole by decreasing its absorption. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Itraconazole may increase the effect of carbamazepine.</td></tr><tr><td><a href="/drugs/DB04846">Celiprolol</a></td><td>Itaconazole increases levels/effect of celiprolol</td></tr><tr><td><a href="/drugs/DB00439">Cerivastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00475">Chlordiazepoxide</a></td><td>Itraconazole may increase the effect of the benzodiazepine, chlordiazepoxide.</td></tr><tr><td><a href="/drugs/DB01410">Ciclesonide</a></td><td>Increased effects/toxicity of ciclesonide</td></tr><tr><td><a href="/drugs/DB01166">Cilostazol</a></td><td>Itraconazole may increase the effect of cilostazol.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>The H2-receptor antagonist, cimetidine, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB01012">Cinacalcet</a></td><td>Itraconazole may increase the effect and toxicity of cinacalcet.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide, clarithromycin, may increase the effect and toxicity of itraconazole.</td></tr><tr><td><a href="/drugs/DB01068">Clonazepam</a></td><td>Itraconazole may increase the effect of the benzodiazepine, clonazepam.</td></tr><tr><td><a href="/drugs/DB00628">Clorazepate</a></td><td>Itraconazole may increase the effect of the benzodiazepine, clorazepate.</td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Itraconazole may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01219">Dantrolene</a></td><td>Itraconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if itraconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00496">Darifenacin</a></td><td>This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>Itraconazole may increase the effect of the benzodiazepine, diazepam.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Itraconazole may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Itraconazole increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00204">Dofetilide</a></td><td>This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Itraconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. </td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan</td></tr><tr><td><a href="/drugs/DB00700">Eplerenone</a></td><td>Itraconazole may increase the effect and toxicity of eplerenone.</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00530">Erlotinib</a></td><td>Itraconazole may decrease the metabolism of erlotinib. Monitor for changes in the therapeutic and adverse effects of erlotinib if itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of itraconazole.</td></tr><tr><td><a href="/drugs/DB00736">Esomeprazole</a></td><td>The proton pump inhibitor, esomeprazole, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB01215">Estazolam</a></td><td>Itraconazole may increase the effect of the benzodiazepine, estazolam.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Phenytoin decreases the effect of itraconazole</td></tr><tr><td><a href="/drugs/DB01590">Everolimus</a></td><td>Itraconazole may increase everolimus levels/toxicity.</td></tr><tr><td><a href="/drugs/DB00927">Famotidine</a></td><td>The H2-receptor antagonist, famotidine, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>Itraconazole may increase the therapeutic and adverse effects of felodipine.</td></tr><tr><td><a href="/drugs/DB00813">Fentanyl</a></td><td>Itraconazole may increase levels/toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB00690">Flurazepam</a></td><td>Itraconazole may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Phenytoin decreases the effect of itraconazole</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of gefitinib. Monitor for changes in the therapeutic and adverse effects of gefitinib if itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00801">Halazepam</a></td><td>Itraconazole may increase the effect of the benzodiazepine, halazepam.</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Itraconazole may increase the effect and toxicity of haloperidol.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Itraconazole may increase the levels of imatinib.</td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>The macrolide, josamycin, may increase the effect and toxicity of itraconazole.</td></tr><tr><td><a href="/drugs/DB00448">Lansoprazole</a></td><td>The proton pump inhibitor, lansoprazole, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB01227">Levomethadyl Acetate</a></td><td>Itraconazole increases the effect/toxicity of levomethadyl</td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB08815">Lurasidone</a></td><td>Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. </td></tr><tr><td><a href="/drugs/DB01377">Magnesium oxide</a></td><td>The antacid, magnesium oxide, may decrease the effect of itraconazole by decreasing its absorption. </td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Phenytoin decreases the effect of itraconazole</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone.</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Itraconazole may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00585">Nizatidine</a></td><td>The H2-receptor antagonist, nizatidine, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>The proton pump inhibitor, omeprazole, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB00213">Pantoprazole</a></td><td>The proton pump inhibitor, pantoprazole, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>The barbiturate, phenobarbital, decreases the effect of itraconazole.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin decreases the effect of itraconazole</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB01589">Quazepam</a></td><td>Itraconazole may increase the effect of the benzodiazepine, quazepam.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Itraconazole may increase the effect and toxicity of quinidine.</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Itraconazole may increase the effect and toxicity of quinidine barbiturate.</td></tr><tr><td><a href="/drugs/DB01129">Rabeprazole</a></td><td>The proton pump inhibitor, rabeprazole, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB00863">Ranitidine</a></td><td>The H2-receptor antagonist, ranitidine, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Increased levels of ranolazine - risk of toxicity</td></tr><tr><td><a href="/drugs/DB08896">Regorafenib</a></td><td>Strong CYP3A4 inhibitors may increase levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin decreases the effect of itraconazole</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of itraconazole.</td></tr><tr><td><a href="/drugs/DB00734">Risperidone</a></td><td>Increases the level of risperidone</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Itraconazole may increase the effect and toxicity of ritonavir.</td></tr><tr><td><a href="/drugs/DB06228">Rivaroxaban</a></td><td>Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.</td></tr><tr><td><a href="/drugs/DB08877">Ruxolitinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00203">Sildenafil</a></td><td>Itraconazole may increase the effect and toxicity of sildenafil.</td></tr><tr><td><a href="/drugs/DB06207">Silodosin</a></td><td>Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated. </td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>Itraconazole may increase the effect and toxicity of sirolimus.</td></tr><tr><td><a href="/drugs/DB01591">Solifenacin</a></td><td>This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism</td></tr><tr><td><a href="/drugs/DB00364">Sucralfate</a></td><td>Sucralfate may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB01268">Sunitinib</a></td><td>Possible increase in sunitinib levels</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>The antifungal, Itraconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Itraconazole therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Itraconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Itraconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Itraconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Itraconazole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Itraconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Itraconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00444">Teniposide</a></td><td>The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00906">Tiagabine</a></td><td>The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir may increase the serum concentration of Itraconazole.</td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Itraconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Itraconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. </td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Itraconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Itraconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Itraconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Itraconazole may increase the effect of the benzodiazepine, triazolam.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Itraconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB08867">Ulipristal</a></td><td>Concomitant therapy with strong CYP3A4 inhibitors may increase plasma concentrations of ulipristal. Avoid combination therapy. </td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Itraconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Itraconaole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Itraconazole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Itraconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00361">Vinorelbine</a></td><td>Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism and/or increasing its efflux. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Itraconazole is initiated, discontinued or dose changed.
</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Itraconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00425">Zolpidem</a></td><td>Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if itraconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00909">Zonisamide</a></td><td>Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01198">Zopiclone</a></td><td>Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if itraconzole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.</li>
<li>Avoid taking with grapefruit juice.</li>
<li>Take after a full meal.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>